| 1001/1816 | US=47 / Câncer Klein C, Vassilev LT. Targeting the p53/MDM2 pathway for cancer therapy. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 19-56. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. SEGMENTACAO DA VIA P53/MDM2; TERAPIA DE CANCER; PROTEINA P53; MDM2; SUPRESSOR DE TUMOR; INTERACAO PROTEINA-PROTEINA; INTERACAO P53-MDM2 |
| 1002/1816 | US=47 / Câncer Bender RP, Osheroff N. DNA topoisomerases as targets for the chemotherapeutic treatment of cancer. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 57-91. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. TOPOISOMERASES DE DNA; CANCER. TERAPIA; QUIMIOTERAPIA; TOPOISOMERASE II; TOPOISOMERASE IIALFA; TOPOISOMERASE IIBETA; TOPOISOMERASE II POISONS; FARMACOS ANTICANCERIGENOS; GENOTOXICIDADE; LEUCEMIA; DNA SUPERCOILING; LESAO DNA |
| 1003/1816 | US=47 / Câncer Ackermann JM, El-Deiry WS. Targeting ATM/ATR in the DNA damage checkpoint. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 93-116. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. SEGMENTACAO ATM/ATR; DANOS AO DNA; ATAXIA TELANGIECTASIA; RADIACAO IONIZANTE; FOSFORILACAO |
| 1004/1816 | US=47 / Câncer Kawabe T. Compounds that abrogate the G2 checkpoint. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 117-33. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. CICLO CELULAR; G1; G2; ONCOGENESE; TERAPIA DO CANCER; DANOS AO DNA; REPARO DO DNA; MUTACAO |
| 1005/1816 | US=47 / Câncer Yap TA, Molife LR, Bono JS. CDK inhibitors as anticancer agents. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 135-62. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES DE CDK; AGENTES ANTICANCERIGENOS; CICLO CELULAR; CICLINA DEPENDENTE DE QUINASE; CICLINA; INIBIDOR; FLAVOPIRIDOL; UCN-01; E7070; SELICICLIB; BMS 387032; ZD 304709 |
| 1006/1816 | US=47 / Câncer Toyota M, Kashima L, Tokino T. CHFR as a potential anticancer target. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 163-76. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. CHFR; AGENTE ANTICANCERIGENO; CHECKPOINT MITOTICO; CHECKPOINT PROFASE; TUBULINA; UBIQUITINA LIGASE E3; MITOSE |
| 1007/1816 | US=47 / Câncer Villalona-Calero MA, Schaaf L, Turowski R. Antimicrotubule agents. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 177-205. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. AGENTES ANTIMICROTUBULOS; TUBULINA; ALCALOIDES DA VINCA; TAXANOS; EPOTILONAS; RESISTENCIA TUMOR; ALBUMINA |
| 1008/1816 | US=47 / Câncer Sarli V, Giannis A. Kinesin motor inhibitors as effective anticancer drugs. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 207-26. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES KINESIN; DROGAS ANTICANCER; KINESINAS; ANTIMITOTICOS; EG5 HUMANA |
| 1009/1816 | US=47 / Câncer Kang J, Yu H. Targeting the spindle checkpoint in cancer chemotherapy. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 227-41. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. SEGMENTACAO DO CHECKPOINT MITOTICO; QUIMIOTERAPIA; MITOSE; SEGREGACAO DOS CROMOSSOMOS; CHECKPOINT MITOTICO; ANEUPLOIDIA; ANAFASE; UBIQUITINACAO; ANTIMITOTICOS; MAD2; CDC20; BUB1 |
| 1010/1816 | US=47 / Câncer Shakalya K, Mahadevan D. Antiproliferation inhibitors targeting aurora kinases. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 243-69. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES ANTI-PROLIFERACAO; AURORA QUINASE; MITOSE; CICLO CELULAR; PROTO-ONCOGENES; INIBIDORES DA PROTEINA-QUINASE; ANEUPLOIDIA; CITOCINESE |
| 1011/1816 | US=47 / Câncer Dai W, Yang Y, Jiang N. Plks as novel targets for cancer drug design. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 271-90. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. PLKS; MEDICAMENTO ANTICANCER; POLO-LIKE QUINASES; PLK1; MITOSE; INIBIDORES; DROGAS ANTI-CANCER; FOSFORILACAO |
| 1012/1816 | US=47 / Câncer Gabrielli B, Stevens F, Beamish H. Do histone deacetylase inhibitors target cell cycle checkpoints that monitor heterochromatin structure?. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 291-309. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES DAS HISTONAS DESACETILASES; CONTROLE DO CICLO CELULAR; HETEROCROMATINA; LETALIDADE SINTETICA; PASSAGEIROS CROMOSSOMICOS |
| 1013/1816 | US=51 / Câncer Cohen L, Markman M. Introduction. In: ___. Integrative oncology: incorporating complementary medicine into conventional cancer care. Totowa: Humana Press, 2008. p. 3-7. ISBN 978-1-58829-869-0. ONCOLOGIA; MEDICINA INTEGRATIVA; MEDICINA COMPLEMENTAR; CENTROS DE CANCER |
| 1014/1816 | US=51 / Câncer Markman M. A word of caution: risk of harm associated with alternative complementary/integrative approaches in cancer management and the critical need for quality research to understand and decrease that risk. In: Cohen L, Markman M. Integrative oncology: incorporating complementary medicine into conventional cancer care. Totowa: Humana Press, 2008. p. 9-13. ISBN 978-1-58829-869-0. QUIMIOTERAPIA; TOXICIDADE DE AGENTES FARMACEUTICOS; GESTAO DE CANCER AVANCADO; MEDICAMENTOS FITOTERAPICOS |
| 1015/1816 | US=51 / Câncer Cohen MH. Using legal and ethical principles to guide clinical decision making in complementary/integrative cancer medicine. In: Cohen L, Markman M. Integrative oncology: incorporating complementary medicine into conventional cancer care. Totowa: Humana Press, 2008. p. 15-32. ISBN 978-1-58829-869-0. RESPONSABILIDADE; NEGLIGENCIA MEDICA; CONSENTIMENTO INFORMADO; COMPLEMENTAR; MEDICINA ALTERNATIVA; CANCRO MEDICINA |
| 1016/1816 | US=51 / Câncer Frenkel M, Ben-Arye E. Communicating with patients about the use of complementary and integrative medicine in cancer care. In: Cohen L, Markman M. Integrative oncology: incorporating complementary medicine into conventional cancer care. Totowa: Humana Press, 2008. p. 33-46. ISBN 978-1-58829-869-0. COMUNICACAO; INTEGRATIVA; MEDICINA; COMUNICACAO MEDICO-PACIENTE; TRATAMENTO DO CANCER; MEDICINA COMPLEMENTAR; CUIDADO CENTRADO NO PACIENTE |
| 1017/1816 | US=51 / Câncer Cohen L, Baynham-Fletcher L, Kirkwood C. The integrative medicine program at the university of texas M.D Anderson cancer center. In: Cohen L, Markman M. Integrative oncology: incorporating complementary medicine into conventional cancer care. Totowa: Humana Press, 2008. p. 49-65. ISBN 978-1-58829-869-0. MEDICINA INTEGRATIVA; ONCOLOGIA; CUIDADO CENTRADO PACIENTE; EDUCACAO |
| 1018/1816 | US=51 / Câncer Cassileth B, Gubili J. The integrative medicine service at memorial slon-kettering cancer center. In: Cohen L, Markman M. Integrative oncology: incorporating complementary medicine into conventional cancer care. Totowa: Humana Press, 2008. p. 67-78. ISBN 978-1-58829-869-0. CANCER; CONTROLE DOS SINTOMAS; TERAPIAS COMPLEMENTARES; ONCOLOGIA INTEGRATIVA |
| 1019/1816 | US=51 / Câncer Rosenthal DS, Doherty-Gilman A, Medeiros C, DeCristofaro S, Dean-Clower E. Integrative oncology-Leonard P.Zakim center: the dana-ferber cancer institute experience. In: Cohen L, Markman M. Integrative oncology: incorporating complementary medicine into conventional cancer care. Totowa: Humana Press, 2008. p. 79-103. ISBN 978-1-58829-869-0. ONCOLOGIA INTEGRATIVA; TERAPIAS INTEGRATIVAS; TRATAMENTO DO CANCER; TERAPIAS COMPLEMENTARES; ACUPUNTURA; DANA-FARBER |
| 1020/1816 | US=51 / Câncer Menten K, Lee S, Dobs AS. The Johns Hopkins complementary and integrative medicine service. In: Cohen L, Markman M. Integrative oncology: incorporating complementary medicine into conventional cancer care. Totowa: Humana Press, 2008. p. 105-21. ISBN 978-1-58829-869-0. JOHNS HOPKINS; MEDICINA INTEGRATIVA; DESAFIOS; ACUPUNTURA; MASSAGEM; MENTE-CORPO CLASSE |